Teva closes Cidra plant
Executive Summary
Teva announces Aug. 23 that it will cease production at its Cidra, Puerto Rico manufacturing facility in the fourth quarter as part of a "globalization rationalization strategy." During a recent earnings call, Teva said it wanted to "significantly reduce complexity" at the facility, which was inherited through its acquisition of Ivax, due to repeated problems (1"The Pink Sheet" Aug. 14, 2006, p. 7). The facility currently employs 550 personnel and originally manufactured 50 products, the majority of which Teva says have been transferred to other sites. The company anticipates the closure will result in approximately $45 mil. in cost savings in 2007...
You may also be interested in...
Teva’s Generic Zoloft Launch, And New Jerusalem Plant, Remain Idle
Teva's supply chain challenges appear to have caught up with the company in the form of further delays of its launch of Zoloft generics
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.